That's not how it works at all.
No matter how big the database used for historical control is, a randomised control trial will be a more powerful study on the hierarchy of evidence based medicine, purely because it is the best way of reducing bias.
You can still have poorly designed RCTs, absolutely. But that's not really what we are discussing.
I don't really understand what you are saying about "unicorn" drug.
I'm assuming this is some take on my critique of their poor choice in control groups for chronic back pain.
That's very different from my critiques of their other trials/theories. But I don't think you've actually taken any of those on board. At least it don't seem like it with that comment.
"frankly utterly stupidly ridiculous unequivocally....." What concise argument. I'm sold!
2022 ... Get your popcorn out!, page-687
-
- There are more pages in this discussion • 92 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
-0.030(2.03%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $1.48 | $1.51 | $1.43 | $6.613M | 4.498M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2482 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 27045 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |